Ethics declarations Conflict of Interest Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, Michelangelo La Placa, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi and Michela Starace is an Editorial Board member of Dermatology and Therapy
Patients with T2D are at heightened risk for cardiovascular (CV) disease, which remains the leading cause of morbidity and mortality in this population ( Over the past decade, glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a promising class of drugs for the management of T2D ( To address these gaps, this systematic review and meta-analysis represents the most up-to-date and comprehensive evaluation of the effects of semaglutide on arrhythmic, major CV, and microvascular outcomes in patients with T2D
Learn more on our comprehensive ED treatment page
Originally developed to help manage type 2 diabetes, semaglutide has become one of the most effective and trusted medical weight loss solutions available
Hayashi, M., Ishibashi, T., Kuwahara, D., & Hirasawa, K